

For a new leap into the global market, we have recently changed our company name from Taerim Pharmaceutical to Pharmaking Co., Ltd. with a new management under CEO Kim Wan Bae.

Since 1988, we became one of the leading R&D-oriented biotechnology venture through its continuous efforts to develop unique medicines for the improvement of human health and eradication of diseases. We are the industry leader in the field of hepatitis medicine.

After the introduction of the Substance Patent System in 1987, we realized that the future of medicine manufacturers would depend on developing competitive medicines. We have been investing more than 20% of our total sales into R&D for the development of new medicines. As a result, the first hepatitis medicine in Korea named "Nissel" was developed in July 1990. Furthermore, after obtaining a patent for a new hepatitis medicine and completing the phase III clinical trial, "Pennel" was launched in Feb. 1998. At the present, "Pennel" capsule is the most popular drug against the hepatitis in Korea and its superiority has been widely recognized in numerous Southeast Asian countries including Vietnam. Recently, Pharmaking started to export "Pennel" to Egypt.

Through extensive experience in research and development, we strive to constantly develop new drugs for the treatment against adult diseases using natural substances. For the first time in the world, we obtained the patent on the hepatitis C drug and are actively preparing to commercialize it. At the same time, we manufacture Generic Pharmaceutical products and have a sales and marketing team nationwide. We also have much experience in regulatory approval on fast track basis from K-FDA based upon our knowledge and human relationship with the K-FDA since 1975.

Since our establishment, we have made every effort to improve the health of people around the world. We will continue to exert our best to become a respectful company that thrives to make the world without any diseases.